Oruka Therapeutics, Inc. (ORKA) — Financial statements
Income statement, balance sheet, and cash flow for Oruka Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.08↑207.4% | 0.03↓75.7% | 0.11↓2.6% | 0.11↑25.3% | 0.09 | |
| Gross Profit | -0.08↓207.4% | -0.03↑75.7% | -0.11↑2.6% | -0.11↓25.3% | -0.09 | |
| Operating Expenses | ||||||
| R&D Expenses | 101↑34.1% | 75↑7309.7% | 1↓77.3% | 4↓67.7% | 14 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 21↑63.6% | 13↑111.2% | 6↑17.3% | 5↓2.8% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 122↑38.4% | 88↑1126.1% | 7↓26.1% | 10↓49.5% | 19 | |
| Total Costs & Expenses | 122↑38.5% | 88↑1107.8% | 7↓25.9% | 10↓49.1% | 19 | |
| Operating Results | ||||||
| Operating Income | -122↓38.5% | -88↓1107.8% | -7↑25.9% | -10↑49.1% | -19 | |
| Depreciation & Amortization | 0.08↑207.4% | 0.03↓75.7% | 0.11↓2.6% | 0.11↑25.3% | 0.09 | |
| EBITDA | -122↓48.3% | -82↓1472.9% | -5↑46.7% | -10↑49.0% | -19 | |
| EBIT | -122↓48.4% | -82↓1440.7% | -5↑46.2% | -10↑48.6% | -19 | |
| Interest & Other Income | ||||||
| Net Interest Income | 17↑278.4% | 4↑124.6% | 2↑189.9% | 0.68 | 0.00 | |
| Interest Income | 17↑183.6% | 6↑199.6% | 2↑189.9% | 0.68 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 1 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -6↓199.8% | -2↓2402.4% | 0.09↑753.8% | -0.01 | |
| Other Income / Expenses | 17↑277.8% | 4↑124.8% | 2↑2402.4% | -0.09↓753.8% | 0.01 | |
| Income Before Tax | -105↓25.9% | -84↓1468.2% | -5↑46.2% | -10↑48.6% | -19 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -105↓25.9% | -84↓1468.2% | -5↑46.2% | -10↑48.6% | -19 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -105↓25.9% | -84↓1468.2% | -5↑46.2% | -10↑48.6% | -19 | |
| Bottom-Line Net Income | -105↓25.9% | -84↓1468.2% | -5↑46.2% | -10↑48.6% | -19 | |
| EPS (Basic) | -2.31↑53.7% | -4.99↓12.4% | -4.44↑46.3% | -8.27↑50.4% | -16.68 | |
| EPS (Diluted) | -2.31↑53.7% | -4.99↓12.4% | -4.44↑46.3% | -8.27↑50.4% | -16.68 | |
| Weighted Average Shares | 46↑171.7% | 17↑16.5% | 14↑0.0% | 14↑3.6% | 14 | |
| Weighted Average Diluted Shares | 46↑171.7% | 17↑16.5% | 14↑0.0% | 14↑3.6% | 14 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.